IP Library › Granted Patent US 12,344,658
Granted Patent B2
US 12,344,658 · App. 17/386,437 · Granted Jul 1, 2025

Nanoparticle formulations

Inventors: Brian Curtis Turner (Denver, CO); Yosef Refaeli (Denver, CO); Gregory Alan Bird (Littleton, CO)
Assignee: HTYR Acquistion LLC
C07K14/82B82Y5/00C07K14/4702C07K14/7051C07K14/70514C07K14/70517C12N5/0636A61K38/00A61P37/02C07K2319/10C07K2319/41C12N2501/606
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,344,658
App. No.
17/386,437
Granted
Jul 1, 2025
Kind
B2
Abstract

This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.

Claims (27)

1. A method of increasing one or more of activation, survival, or proliferation of one or more immune cells or increasing an immune response in a subject in need thereof by administering to the subject a therapeutically effective amount of a formulation comprising a population of biologically active nanoparticles comprising one or more MYC-containing polypeptides wherein:

a) the average diameter of the biologically active nanoparticles is between about 80 nm and about 150 nm;

b) the pH of the formulation is at least about pH 6.0, and no greater than about pH 8; and

c) the one or more MYC-containing polypeptides comprises a MYC fusion protein, comprising a protein transduction domain linked to a MYC polypeptide.

2. The method of claim 1 , wherein the one or more immune cells comprise one or more anergic immune cells.

3. The method of claim 1 , wherein the one or more immune cells are T cells.

4. The method of claim 3 , wherein the T cells are selected from the group consisting of native T cells, CD4+ T cells, CD8+ T cells, memory T cells, activated T cells, anergic T cells, tolerant T cells, and antigen-specific T cells.

5. The method of claim 1 , wherein the one or more immune cells are B cells.

6. The method of claim 5 , wherein the B cells are selected from the group consisting of native B cells, plasma B cells, activated B cells, memory B cells, anergic B cells, tolerant B cells, chimeric B cells, and antigen-specific B cells.

7. The method of claim 1 , wherein the MYC polypeptide is acetylated.

8. The method of claim 1 , wherein the MYC fusion peptide further comprises one or more linkers that link the protein transduction domain and the MYC polypeptide.

9. The method of claim 1 , wherein the one or more MYC-containing polypeptides comprises a MYC fusion peptide with the following general structure:

protein transduction domain−X-MYC sequence,

wherein —X— is a linker that links the protein transduction domain and the MYC sequence.

10. The method of claim 1 , wherein the protein transduction domain sequence is a TAT protein transduction domain sequence.

11. The method of claim 10 , wherein the TAT protein transduction domain sequence is selected from the group consisting of TAT[48-57] and TAT[57-48].

12. The method of claim 1 , wherein the MYC polypeptide is a MYC fusion peptide comprising SEQ ID NO: 1 or 10.

13. The method of claim 1 , wherein the nanoparticles have an average diameter of between about 100 nm and about 110 nm.

14. The method of claim 1 , wherein the formulation further comprises a pharmaceutically acceptable excipient.

15. The method of claim 1 , wherein the formulation is formulated for topical administration, oral administration, parenteral administration, intranasal administration, buccal administration, rectal administration, or transdermal administration.

16. The method of claim 1 , wherein the nanoparticles have an average diameter of about 90-140 nm.

17. The method of claim 1 , wherein the nanoparticles have a molecular mass of about 104-106 daltons.

18. The method of claim 1 , wherein the nanoparticles comprise about 200 molecules of the MYC-containing polypeptide.

19. A method of priming hematopoietic stem cells to enhance engraftment, following hematopoietic stem cell transplantation (HSCT) comprising, contacting one or more hematopoietic stem cells, in vitro, prior to transplantation of the hematopoietic stem cells with a composition comprising a population of biologically active nanoparticles comprising one or more MYC-containing polypeptides wherein:

a) the average diameter of the biologically active nanoparticles is between about 80 nm and about 150 nm;

b) the pH of the composition is at least about pH 6.0, and no greater than about pH 8; and

c) the one or more MYC-containing polypeptides comprises a MYC fusion protein, comprising a protein transduction domain linked to a MYC polypeptide.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2024
From: TAIGA BIOTECHNOLOGIES, INC.
To: TAIGA BIOTECHNOLOGIES (ABC), LLC
Reel/Frame 067133/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2024
From: TAIGA BIOTECHNOLOGIES (ABC), LLC
To: HTYR ACQUISITION LLC
Reel/Frame 067133/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2021
From: TURNER, BRIAN CURTIS; REFAELI, YOSEF; BIRD, GREGORY ALAN
To: TAIGA BIOTECHNOLOGIES, INC.
Reel/Frame 056998/0918 →
Continuity (4)
Division 16742082 · Jan 14, 2020
Division 15828971 · Dec 1, 2017
Provisional Application 62429466 · Dec 2, 2016
Related Publication 20220096545A1 · Mar 31, 2022
References Cited (400)
US 4900322A · Adams · 1990 [cited by applicant]
US 4963489A · Naughton et al. · 1990 [cited by applicant]
US 5289858A · Grabenkort · 1994 [cited by applicant]
US 5476996A · Wilson et al. · 1995 [cited by applicant]
US 5652122A · Frankel et al. · 1997 [cited by applicant]
US 5670617A · Frankel et al. · 1997 [cited by applicant]
US 5674980A · Frankel et al. · 1997 [cited by applicant]
US 5698767A · Wilson et al. · 1997 [cited by applicant]
US 5747641A · Frankel et al. · 1998 [cited by applicant]
US 5804604A · Frankel et al. · 1998 [cited by applicant]
US 5811301A · Cameron · 1998 [cited by applicant]
US 5824837A · Chen et al. · 1998 [cited by applicant]
US 5843728A · Seed et al. · 1998 [cited by applicant]
US 5847082A · Rother et al. · 1998 [cited by applicant]
US 5849288A · Reisner · 1998 [cited by applicant]
US 5851828A · Seed et al. · 1998 [cited by applicant]
US 5912170A · Seed et al. · 1999 [cited by applicant]
US 6004811A · Seed et al. · 1999 [cited by applicant]
US 6040177A · Riddell et al. · 2000 [cited by applicant]
US 6284240B1 · Seed et al. · 2001 [cited by applicant]
US 6358739B1 · Baetge et al. · 2002 [cited by applicant]
US 6392013B1 · Seed et al. · 2002 [cited by applicant]
US 6410014B1 · Seed et al. · 2002 [cited by applicant]
US 6451558B1 · Cooke et al. · 2002 [cited by applicant]
US 6451601B1 · Baetge et al. · 2002 [cited by applicant]
US 6645501B2 · Dowdy · 2003 [cited by applicant]
US 6753162B1 · Seed et al. · 2004 [cited by applicant]
US 7135287B1 · Lonberg et al. · 2006 [cited by applicant]
US 7311920B1 · Devico et al. · 2007 [cited by applicant]
US 7582745B2 · Sah et al. · 2009 [cited by applicant]
US 7767453B2 · Zhang · 2010 [cited by applicant]
US 8034334B2 · Dudley et al. · 2011 [cited by applicant]
US 8211422B2 · Eshhar et al. · 2012 [cited by applicant]
US 8481492B2 · Edenhofer · 2013 [cited by examiner]
US 8637307B2 · June et al. · 2014 [cited by applicant]
US 8697854B2 · Schendel et al. · 2014 [cited by applicant]
US 8784825B2 · Refaeli et al. · 2014 [cited by applicant]
US 8828723B2 · Refaeli et al. · 2014 [cited by applicant]
US 8986702B2 · Refaeli et al. · 2015 [cited by applicant]
US 9150831B2 · Cambier et al. · 2015 [cited by applicant]
US 9169462B2 · Refaeli et al. · 2015 [cited by applicant]
US 9365825B2 · Turner et al. · 2016 [cited by applicant]
US 9775897B2 · Refaeli et al. · 2017 [cited by applicant]
US 9789135B2 · Turner et al. · 2017 [cited by applicant]
US 10087420B2 · Turner et al. · 2018 [cited by applicant]
US 10149898B2 · Refaeli et al. · 2018 [cited by applicant]
US 10442853B2 · Refaeli et al. · 2019 [cited by applicant]
US 10760055B2 · Cambier et al. · 2020 [cited by applicant]
US 10864259B2 · Refaeli et al. · 2020 [cited by applicant]
US 11116796B2 · Turner et al. · 2021 [cited by applicant]
US 11369678B2 · Refaeli et al. · 2022 [cited by applicant]
US 20010049393A1 · Coller et al. · 2001 [cited by applicant]
US 20020055478A1 · Faris et al. · 2002 [cited by applicant]
US 20020076787A1 · Baetge et al. · 2002 [cited by applicant]
US 20020098166A1 · Havemann et al. · 2002 [cited by applicant]
US 20020155502A1 · Balint et al. · 2002 [cited by applicant]
US 20030072794A1 · Boulikas · 2003 [cited by applicant]
US 20030138859A1 · Barbera-Guillem et al. · 2003 [cited by applicant]
US 20030220286A1 · Abruzzese et al. · 2003 [cited by applicant]
US 20040224402A1 · Bonyhadi et al. · 2004 [cited by applicant]
US 20050220705A1 · Brooks et al. · 2005 [cited by applicant]
US 20050281816A1 · Lamping et al. · 2005 [cited by applicant]
US 20060068369A1 · Coelho et al. · 2006 [cited by applicant]
US 20060068469A1 · Payne et al. · 2006 [cited by applicant]
US 20060115898A1 · Zhang et al. · 2006 [cited by applicant]
US 20060154331A1 · Avidan et al. · 2006 [cited by applicant]
US 20060156422A1 · Dalrymple et al. · 2006 [cited by applicant]
US 20060222657A1 · Dowdy et al. · 2006 [cited by applicant]
US 20070011753A1 · Ito et al. · 2007 [cited by applicant]
US 20070047583A1 · Assa et al. · 2007 [cited by applicant]
US 20070067854A1 · Habu et al. · 2007 [cited by applicant]
US 20070082397A1 · Hasson et al. · 2007 [cited by applicant]
US 20070093420A1 · Yeomans et al. · 2007 [cited by applicant]
US 20070098715A1 · Ettenberg et al. · 2007 [cited by applicant]
US 20070116691A1 · Cambier et al. · 2007 [cited by applicant]
US 20070130628A1 · Brown · 2007 [cited by applicant]
US 20070248618A1 · Cohen · 2007 [cited by applicant]
US 20080050396A1 · Andersen et al. · 2008 [cited by applicant]
US 20090291094A1 · Refaeli et al. · 2009 [cited by applicant]
US 20100047217A1 · Refaeli et al. · 2010 [cited by applicant]
US 20100055129A1 · Refaeli et al. · 2010 [cited by applicant]
US 20100233804A1 · Zhou et al. · 2010 [cited by applicant]
US 20100279351A1 · Refaeli · 2010 [cited by applicant]
US 20100297763A1 · Cambier et al. · 2010 [cited by applicant]
US 20110218210A1 · Refaeli et al. · 2011 [cited by applicant]
US 20120003189A1 · Pelus et al. · 2012 [cited by applicant]
US 20120027792A1 · Pavlakis et al. · 2012 [cited by applicant]
US 20120244133A1 · Rosenberg et al. · 2012 [cited by applicant]
US 20120251563A1 · Nicchitta et al. · 2012 [cited by applicant]
US 20130177586A1 · Refaeli et al. · 2013 [cited by applicant]
US 20140109246A1 · Jimeno et al. · 2014 [cited by applicant]
US 20140255369A1 · Turner et al. · 2014 [cited by applicant]
US 20140356392A1 · Refaeli et al. · 2014 [cited by applicant]
US 20150164950A1 · Turner et al. · 2015 [cited by applicant]
US 20150218515A1 · Altrichter et al. · 2015 [cited by applicant]
US 20170044500A1 · Cooper et al. · 2017 [cited by applicant]
US 20180036396A1 · Refaeli et al. · 2018 [cited by applicant]
US 20190060434A1 · Refaeli et al. · 2019 [cited by applicant]
US 20200215188A1 · Refaeli et al. · 2020 [cited by applicant]
US 20210121550A1 · Refaeli et al. · 2021 [cited by applicant]
AU 2762802A1 · 2002 [cited by applicant]
AU 2006304392A1 · 2007 [cited by applicant]
CA 2584738A1 · 2006 [cited by applicant]
CA 2626525A1 · 2007 [cited by applicant]
CN 1357620A · 2002 [cited by applicant]
CN 101045914A · 2007 [cited by applicant]
CN 101330830A · 2008 [cited by applicant]
CN 102027105A · 2011 [cited by applicant]
CN 102083960A · 2011 [cited by applicant]
CN 104353066A · 2015 [cited by applicant]
EP 036776A2 · 1981 [cited by applicant]
EP 0213469A2 · 1987 [cited by applicant]
EP 1103615A1 · 2001 [cited by applicant]
EP 1357184 · 2003 [cited by applicant]
EP 1792627 · 2007 [cited by applicant]
GB 2387599 · 2003 [cited by applicant]
JP 2000189157 · 2000 [cited by applicant]
JP 2001518300 · 2001 [cited by applicant]
JP 2002541786A · 2002 [cited by applicant]
JP 2003513672A · 2003 [cited by applicant]
JP 2003514565 · 2003 [cited by applicant]
JP 2004519245A · 2004 [cited by applicant]
JP 2005523012 · 2005 [cited by applicant]
JP 2005525085 · 2005 [cited by applicant]
JP 2005232148A · 2005 [cited by applicant]
JP 2005527211 · 2005 [cited by applicant]
JP 2006519781A · 2006 [cited by applicant]
JP 2009511081A · 2009 [cited by applicant]
JP 2011528567A · 2011 [cited by applicant]
JP 2012501347A · 2012 [cited by applicant]
JP 2014527980A · 2014 [cited by applicant]
JP 2015524415A · 2015 [cited by applicant]
JP 6167130B2 · 2015 [cited by applicant]
JP 2015525209A · 2015 [cited by applicant]
JP 2016510996A · 2016 [cited by applicant]
JP 2017513498 · 2017 [cited by applicant]
JP 6484293B2 · 2019 [cited by applicant]
JP 6655050B2 · 2020 [cited by applicant]
WO WO8603780A1 · 1986 [cited by applicant]
WO WO9215322 · 1992 [cited by applicant]
WO WO9404686 · 1994 [cited by applicant]
WO WO9419465 · 1994 [cited by applicant]
WO WO9514078 · 1995 [cited by applicant]
WO WO9810058 · 1998 [cited by applicant]
WO WO9852614 · 1998 [cited by applicant]
WO WO9916884 · 1999 [cited by applicant]
WO WO9945962 · 1999 [cited by applicant]
WO WO9953023 · 1999 [cited by applicant]
WO WO9953028 · 1999 [cited by applicant]
WO WO0009669 · 2000 [cited by applicant]
WO WO0061617A2 · 2000 [cited by applicant]
WO WO0062067 · 2000 [cited by applicant]
WO WO0134824A2 · 2001 [cited by applicant]
WO WO0138548 · 2001 [cited by applicant]
WO WO02057436 · 2002 [cited by applicant]
WO WO02074968A1 · 2002 [cited by applicant]
WO WO03020763 · 2003 [cited by applicant]
WO WO03033701 · 2003 [cited by applicant]
WO WO03038057 · 2003 [cited by applicant]
WO WO03039462 · 2003 [cited by applicant]
WO WO03057171 · 2003 [cited by applicant]
WO WO03089580 · 2003 [cited by applicant]
WO WO03089630 · 2003 [cited by applicant]
WO WO03094849 · 2003 [cited by applicant]
WO WO03097675 · 2003 [cited by applicant]
WO WO2004033685 · 2004 [cited by applicant]
WO WO2004035535 · 2004 [cited by applicant]
WO WO2004044004 · 2004 [cited by applicant]
WO WO2004050885 · 2004 [cited by applicant]
WO WO2004074322 · 2004 [cited by applicant]
WO WO2004084805 · 2004 [cited by applicant]
WO WO2005014785 · 2005 [cited by applicant]
WO WO2005049073A2 · 2005 [cited by applicant]
WO WO2005084158 · 2005 [cited by applicant]
WO WO2005113595 · 2005 [cited by applicant]
WO WO2005114215 · 2005 [cited by applicant]
WO WO2006000830 · 2006 [cited by applicant]
WO WO2006032876 · 2006 [cited by applicant]
WO WO2006116512 · 2006 [cited by applicant]
WO WO2006125962 · 2006 [cited by applicant]
WO WO2007047583A2 · 2007 [cited by applicant]
WO WO2007067183 · 2007 [cited by applicant]
WO WO2008038002 · 2008 [cited by applicant]
WO WO2008039818 · 2008 [cited by applicant]
WO WO2008112922 · 2008 [cited by applicant]
WO WO2009059304 · 2009 [cited by applicant]
WO WO2009139930A2 · 2009 [cited by applicant]
WO WO2010011644 · 2010 [cited by applicant]
WO WO2010025421A2 · 2010 [cited by applicant]
WO WO2011100477A2 · 2011 [cited by applicant]
WO WO2012055170 · 2012 [cited by applicant]
WO WO2013039889 · 2013 [cited by applicant]
WO WO2013166321 · 2013 [cited by applicant]
WO WO2014018863 · 2014 [cited by applicant]
WO WO2014039908A1 · 2014 [cited by applicant]
WO WO2014083173 · 2014 [cited by applicant]
WO WO2014133567 · 2014 [cited by applicant]
WO WO2014133568 · 2014 [cited by applicant]
WO WO2014164606A1 · 2014 [cited by applicant]
WO WO2016105542A2 · 2016 [cited by applicant]
WO WO2017059319A2 · 2017 [cited by applicant]
WO WO2017123978A1 · 2017 [cited by applicant]
WO WO2018104909A2 · 2018 [cited by applicant]
Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene—the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. Jan. 2022;19(1):23-36. doi: 10.1038/s41… [cited by examiner]
Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. Sep. 3, 1999;285(5433):1569-72. doi: 10.1126/science.285.5433.1569. PMID: 10… [cited by examiner]
Madden SK, de Araujo AD, Gerhardt M, Fairlie DP, Mason JM. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. Mol Cancer. Jan. 4, 2021;20(1):3. doi: 10.1186/s12943-020-01291-6. PMID: … [cited by examiner]
Chen Y, Bathula SR, Yang Q, Huang L. Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol. Dec. 2010;130(12):2790-8. doi: 10.1038/jid.2010.222. Epub Aug. 5, 2010. PMID: 20686495. (Year: 2010). [cited by examiner]
Tangudu NK, et al. RNA Interference Using c-Myc-Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models. Mol Cancer Ther. May 2015;14(5):1259-69. doi: 10.1158/1535-7163.MCT-14-0970. Epub Feb. 18, 2015. P… [cited by examiner]
Yu et al., “Molecular Biology” (in Chinese), Nanjing Normal University Press, Jul. 2007, pp. 158 and 159 (English Translation). [cited by applicant]
Zhu et al., “Modern Molecular Biology” (in Chinese), Higher Education Press, Mar. 1997, p. 422 (English Translation). [cited by applicant]
Hann, et al., “The alternatively initiated c-Myc proteins differentially regulate transcription through a noncanonical DNA-binding site.” Genes & Development, 1994, No. 8, pp. 2441-2452. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 16/635,383 dated Jun. 29, 2022. [cited by applicant]
Examination Report for CA 3065947 dated Oct. 13, 2021 (4 pages). [cited by applicant]
Extended European Search Report for EP 21170329.3 dated Oct. 22, 2021 (10 pages). [cited by applicant]
Foreign Search Report and Written Opinion issued for SG Appl. Ser. No. 10201707390V dated Oct. 13, 2021 (9 pages). [cited by applicant]
International Preliminary Report on Patentability, Ch. I, for PCT/US2020/027070 dated Oct. 21, 2021 (9 pages). [cited by applicant]
Reasons for Refusal for JP 2020-193475 dated Oct. 25, 2021 (4 pages). [cited by applicant]
Caron, et al., “Intracellular Delivery of a Tat-eGFP Fusion Protein into Muscle Cells.” Molecular Therapy, Mar. 2001, vol. 3, No. 3, pp. 310-318. [cited by applicant]
Chandran, et al., “Tumor-Specific Effector CD8 T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.” Cancer Res. Aug. 15, 2015, vol. 75, N… [cited by applicant]
Deleeuw, et al., “CD25 Identifies a Subset of CD4 FoxP3-TIL That Are Exhausted Yet Prognostically Favorable in Human Ovarian Cancer.” Cancer Immunol. Res. Mar. 1, 2015, vol. 3, No. 3, pp. 245-253. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 16/598,690 dtd Mar. 1, 2022. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 16/635,383 dtd Feb. 18, 2022. [cited by applicant]
Vives, et al., “A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus.” Journal of Biol. Chemistry. Jun. 20, 1997, vol. 272, No. 25, pp. 16010-16… [cited by applicant]
Wold et al., “Antibody Therapeutics in Oncology”, Immunotherapy, Mar. 2016, pp. 1-18, vol. 2, No. 1. [cited by applicant]
Office Action issued in Canadian Application No. 2905296 dated Feb. 15, 2022. [cited by applicant]
European Communication pursuant to Article 94(3) issued in European Application No. 19157513.3 dated Mar. 3, 2022. [cited by applicant]
Notice of Reasons for Rejection issued in Japanese Application No. 2021-037508, dated Mar. 31, 2022, English Translation. [cited by applicant]
De Clercq, E., “New Nucleotide Analogues for the Treatment of Hemorrhagic Fever Virus Infections.” Chem. Asian J., 2019, vol. 14, pp. 3962-3968. [cited by applicant]
Duraffour, et al., “How to treat Ebola virus infections? A lesson from the field.” Current Opinion in Virology, 2017, vol. 24, pp. 9-15. [cited by applicant]
Fanale, et al., “Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma.” Drugs, 2007, vol. 3, pp. 333-350. [cited by applicant]
Foreign Action other than Search Report on EP 20212922.7 dtd Sep. 1, 2022. [cited by applicant]
Gibson, et al., “How we evaluate and treat neutropenia in adults.” Blood, 2014, vol. 124, No. 8, pp. 1251-1258. [cited by applicant]
Jacobson, et al., “How I treat Burkitt lymphoma in adults.” Blood, 2014, vol. 124, No. 19, pp. 2913-2920. [cited by applicant]
Namikawa, et al., “A case of ABO-incompatible blood transfusion treated by plasma exchange therapy and continuous hemodiafiltration.” CEN Case Reports, 2018, vol. 7, pp. 114-120. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 17/009,279 dtd Oct. 27, 2022. [cited by applicant]
A. Strasser, et al., “Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2”, Letters to Nature 348: 331-333 (1990). [cited by applicant]
Altman, et al., “Phenotypic Analysis of Antigen-Specific I Lymphocytes”, Science 274: 94-96 (1996). [cited by applicant]
Andersen, et al., “Parallel detection of antigen-specific T cell responses by combinatiorial encoding of MHC multimers”, Nature Protocols 7(5): 891-902 (2012). [cited by applicant]
Aubry et al., “N-Myc Shares Cellular Functions with c-Myc”, DNA and Cell Biology, vol. 19, No. 6, Jun. 2000, pp. 353-364. [cited by applicant]
Austrian Search Report and Written Opinion received for Singapore Patent Application No. 201101367-9, mailed on Mar. 23, 2012, 17 pages. [cited by applicant]
Baum, Christopher, “Insertional Mutagenesis in Gene Therapy and Stem Cell Biology”, Current Opinion in Hematology, vol. 14, Jul. 2007, pp. 337-342. [cited by applicant]
Beerens et al., “Protein Transduction Domains and their Utility in Gene Therapy”, Current Gene Therapy, vol. 3, No. 5, 2003, pp. 486-494. [cited by applicant]
Benassayag et al., “Human c-Myc Isoforms Differentially Regulate Cell Growth and Apoptosis in [cited by applicant]
Berkson et al., “Pilot Screening Programme for Small Molecule Activators of p53”, International Journal of Cancer, vol. 115, 2005, pp. 701-710. [cited by applicant]
Bird, et al., “Expansion of Human and Murine Hematopoietic Stem and Progenitor Cells Ex Vivo without Genetic Modification Using MYC and Bcl-2 Fusion Proteins”, PLOS ONE 9(8): e105525 (2014). [cited by applicant]
Bissonnette, et al., “Apoptotic cell death induced by c-myc is inhibited by bcl-2,” Nature 359: 552-554 (Oct. 8, 1992). [cited by applicant]
Bouchard et al., “Control of cell proliferation by Myc”, Trends in Cell Biology, vol. 8, pp. 202-206, (1998). [cited by applicant]
Bunting et al., “Restoration of lymphocyte function in Janus kinase 3-deficient mice by retro-viral-mediated gene transfer,” Nature Medicine 4:58-64 (1998). [cited by applicant]
Buske et al., “Deregulated Expression of HOXB4 Enhances the Primitive Growth Activity of Human Hematopoietic Cells”, Blood, vol. 100, No. 3, Aug. 1, 2002, pp. 862-868. [cited by applicant]
Capecchi, Mario R., “Altering the Genome by Homologous Recombination”, Science, vol. 244, No. 4910, Jun. 16, 1989, pp. 1288-1292. [cited by applicant]
Caron et al., “Endosome disruption enhances the functional nuclear delivery of Tat-fusion proteins”, Biochemical and Biophysical Research Communications 319(1): 12-20 (2004). [cited by applicant]
Carotta et al., “Directed Differentiation and Mass Cultivation of Pure Erythorid Progenitors from Mouse Embryonic Stem Cells”, Blood, vol. 104, No. 6, Sep. 15, 2004, pp. 1873-1880. [cited by applicant]
Chadwick, et al., “Notch Signaling Induces Apoptosis in Primary Human CD34 Hematopoietic Progenitor Cells”, Stem Cells, (2007), vol. 24, pp. 203-210. [cited by applicant]
Chang, et al., “Phenotypic expression in [cited by applicant]
Chen et al., “Small-Molecule Anthracene-Induced Cytotoxicity and Induction of Apoptosis through Generation of Reactive Oxygen Species”, Biological & Pharmaceutical Bulletin, vol. 27, No. 6, Jun. 2004, pp. 838-845. [cited by applicant]
Cheng et al., “BCL-2, BCL-XL, Sequester BH3 Domain-Only Molecules Preventing BAX- and BAK-Mediated Mitochondrial Apoptosis”, Molecular Cell (2001) vol. 8, pp. 705-711. [cited by applicant]
Chi, et al., “Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation,” Pharm. Res., vol. 20, No. 9, Sep. 2003, pp. 1325-1336. [cited by applicant]
Chin et al., “Essential Role for Oncogenic Ras in Tumour Maintenance”, Nature, vol. 400, 1999, pp. 468-472. [cited by applicant]
Choi et al., “Myc Protein is Stabilized by Suppression of a Novel E3 Ligase Complex in Cancer Cells”, Genes & Development, vol. 24, 2010, pp. 1236-1241. [cited by applicant]
Choi, et al., “Status Epilepticus-Induced Somatostatinergic Hilar Interneuron Degeneration is Regulated by Striatal Enriched Protein Tyrosine Phosphatase”, Journal of Neuroscience, (2007), vol. 27, No. 11, pp. 2999-3009. [cited by applicant]
Cleland, et al., “The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation,” Crit. Rev. Ther. Drug Carrier Syst., vol. 70, No. 4, Jan. 1, 1993, pp. 307-377. [cited by applicant]
Coeytaux et al., “The Cationic Amphipathic alpha-Helix of HIV-1 Viral Protein R (Vpr) Binds to Nucleic Acids, Permeabilizes Membranes, and Efficiently Transfects Cells,” The Journal of Biological Chemistry, vol. 278, No… [cited by applicant]
Coller, et al., “Expression Analysis with Oligonucleotide Microarrays Reveals that MYC Regulates Genes Involved in Growth, Cell Cycle, Signaling, and Adhesion”, PNAS, (2000), 97(7):3260-3265. [cited by applicant]
Conti, et al., “Gene therapy using neural stem cells,” Methods Mol. Biol. 198:233-244 (2002). [cited by applicant]
Coppola et al., “Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment,” Nature, vol. 320, Apr. 24, 1986, pp. 760-763. [cited by applicant]
D'Alessandro, et al., “Red blood cell storage: the story so far”, Blood Transfus 8: 82-88 (2010). [cited by applicant]
Dang et al., “Identification of the Human c-myc Protein Nuclear Translocation Signal”, Molecular and Cellular Biology, vol. 8, No. 10, Oct. 1988, pp. 4048-4054. [cited by applicant]
Dang et al., “Nuclear and Nucleolar Targeting Sequences of c-erb-A, c-myb, N-myc, p53, HSP70 and HIV tat Proteins”. Journal of Biological Chemistry, vol. 264, No. 30, pp. 18019-18023 (1989). [cited by applicant]
Dang, Chi V., “c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism”, Molecular and Cellular Biology, vol. 19, No. 1, Jan. 1999, pp. 1-11. [cited by applicant]
Daugas, et al., “Erythrocytes: Death of a mummy”, Cell Death and Differentiation 8(12): 1131-1133 (2001). [cited by applicant]
De Korte, “New additive solutions for red cells”, ISBI Science Series 11: 165-170 (2016). [cited by applicant]
DeBoer, et al., “The tac promoter: A functional hybrid derived from the trp and lac promoters”, Proc. Natl. Acad. Sci. USA 80: 21-25 (1983). [cited by applicant]
Delgado et al., “Myc Roles in Hematopoiesis and Leukemia,” Genes and Cancer, 2010, pp. 605-616. [cited by applicant]
Deocampo, et al., “Cooperation of BCL-2 and MYC in the Neoplastic Transformation of Normal Rat Lever Epithelial Cells is Related to the Down-Regulation of Gap Junction-Mediated Intercellular Communication”, Carcinogenes… [cited by applicant]
Derossi, et al., “Trojan peptides: the penetratin system for intracellular delivery”, Trends Cell Biol. 8: 84-87 (1998). [cited by applicant]
Dmitrovsky et al., “A Transfected c-myc Oncogene Inhibits Mouse Erytholeukemic Differentiation,” Current Topics in Microbiology and Immunology, vol. 132, 1986, 4 pages. [cited by applicant]
Domashenko et al., “TAT-mediated transduction of NF-Ya peptide induces the ex vivo proliferation and egraftment potential of human hematopoietic progenitor cells,” Blood, Oct. 14, 2010, vol. 116, No. 15, pp. 2676-2683. [cited by applicant]
Domen, et al., “The Role of Apoptosis in the Regulation of Hematopoietic Stem Cells: Overexpression of BCL-2 Increase Both Their Number and Repopulation Potential”, J. Exp. Med. 191(2): 253-263 (2000). [cited by applicant]
Dudley, et al., “Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients with Refractory Metastatic Melanoma”, Journal of Clinical Oncology 23(10): 2346-… [cited by applicant]
Dvorak et al., “Cytochemical Localization of Peroxidase Activity in the Developing Erythrocyte,” Am. J. Pathol. 1972, 67(2), pp. 303-326. [cited by applicant]
Eilers, et al., “Chimeras of MYC Oncoprotein and Steroid Receptors Cause Hormone-Dependent Transformation of Cells,” Nature 340(6228):66-68 (1989). [cited by applicant]
Eischen, et al., “Apoptosis Triggered by Myc-Induced Suppression of Bcl-XL or Bcl-2 is Bypassed during Lymphomagenesis”, Molecular Cell Biology, 2001, 21: 5063-5070. [cited by applicant]
Elliot, et al., “Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein”, Cell 88: 223-233 (1997). [cited by applicant]
Esdar, C., et al., “Differentiation-associated apoptosis of neural stem cells is effected by Bcl-2 overexpression: impact on cell lineage determination,” Eur. J. Cell Biol.,(2001), vol. 80, No. 8, pp. 539-553. [cited by applicant]
European Extended Search Report, issued in EP Pat. App. No. 17920607.3, 7 pages (Dec. 11, 2019). [cited by applicant]
European Extended Search Report, issued in European Patent Appln. No. 19157513.3, 13 pages (Apr. 1, 2019). [cited by applicant]
Extended European Search Report and Search Opinion received for Patent Application No. 12187097.6, mailed on Mar. 27, 2013, 8 pages. [cited by applicant]
Extended European Search Report for EP Patent Application No. 13188850.0, dated May 27, 2014, 8 pages. [cited by applicant]
Extended European Search Report on EP 20212922.7 dtd May 26, 2021 (7 pages). [cited by applicant]
Extended European Search Report received for European Patent Application No. 09810692.5, mailed on Jul. 11, 2011, 5 pages. [cited by applicant]
Extended European Search Report received for European Patent Application No. 06826025.6, mailed on Aug. 13, 2009, 8 pages. [cited by applicant]
Extended European Search Report received for European Patent Application No. 09747016.5, mailed on May 30, 2012, 8 pages. [cited by applicant]
Extended European Search Report received for European Patent Application No. 09800871. 7, mailed on Jun. 24, 2011, 5 pages. [cited by applicant]
Extended European Search Report received for European Patent Application No. 12187077.8, mailed on Mar. 25, 2013, 7 pages. [cited by applicant]
Extended Search Report issued on EP Application 13820331.0, mailed Oct. 10, 2016. [cited by applicant]
Extended Search Report issued on European Application 14778538.0, mailed Sep. 29, 2016. [cited by applicant]
Extended Search Report issued on European Application 14779483.8, mailed Dec. 23, 2016. [cited by applicant]
Extended Search Report issued on European Patent Application 15175802.6, mailed Dec. 14, 2015. [cited by applicant]
Extended Search Report on EP 17876016.1 dtd Jun. 26, 2020. [cited by applicant]
Fanidi, et al., “Cooperative interaction between c-myc and bcl-2 proto-oncogenes”, Nature 359: 554-556, abstract only (1992). [cited by applicant]
Felsher, et al., “Reversible Tumorigenesis by MYC in Hematopoietic Lineages”, (1999), Molecular Cell, 4: 199-207. [cited by applicant]
First Written Opinion on SG 11202000612T dtd Jul. 29, 2021 (6 pages). [cited by applicant]
Futaki, Chemistry and Biology (Kagaku to Seibutsu), vol. 43, No. 10, Oct. 1, 2005, p. 649-653 (English translation not available). [cited by applicant]
Gandarillas et al., “C-Myc promotes differentiation of human epidermal stem cells,” Genes & Develoopment, vol. 11, 1997, pp. 2869-2882. [cited by applicant]
Gauss et al., “DEAE-Dextran Enhances Electroportation of Mammalian Cells”, Nucleic Acids Research, vol. 20, No. 4, pp. 6739-6740 (1992). [cited by applicant]
Goeddel, et al. “Synthesis of human fibroblast interferon by [cited by applicant]
Goeddel, et al.,“Direct expression in [cited by applicant]
Grumont et al., “The Mitogen-Induced Increase in T Cell Size Involves PKC and NFAT Activation of Rel/NF-kB-Dependent c-myc Expression,” Immunity, 2004, vol. 21, p. 19-30. [cited by applicant]
Guzman et al., “Preferential induction of apoptosis for primary human leukemic stem cells,” PNAS 99(25):16220-16225 (2002). [cited by applicant]
Habib et al., “Myc Stimulates B Lymphocyte Differentiation and Amplifies Calcium Signaling”, J.Cell Biol., vol. 179, No. 4, 2007, pp. 717-731. [cited by applicant]
Hann et al., “Proteins Encoded by the Human C-Myc Oncogene: Differential Expression in Neoplastic Cells”, Mol. Cell. Biol., vol. 4, No. 11, Nov. 1984, pp. 2486-2497. [cited by applicant]
Henikoff et al., “Amino acid substitution matrices from protein blocks”, Proc. Natl Acad. Sci. USA, 89:10915-10919 (1992). [cited by applicant]
Hiramatsu, et al., “Complete reconstitution of human lymphocytes from cord blood CD34 cells using the NOD/SCID/? c null mice model”, Blood 102(3): 873-880 (2003). [cited by applicant]
Hirose, et al., “Immortalization of Erythroblasts by c-MYC and BCL-XL Enables Large-Scale Erythrocyte Production from Human Pluripotent Stem Cells”, Stell Cell Reports I: 499-508 (2013). [cited by applicant]
Ho, et al., “Synthetic Protein Transduction Domains: Enhanced Transduction Potential in Vitro and in Vivo”, Cancer Research, (2001), vol. 61, pp. 474-477. [cited by applicant]
Hoffman, “Progress in the develoment of systems for in vitro expansion of human hematopoietic stem cells,” Curr. Op. Hematology 6(3): 14 pages (1999). [cited by applicant]
Horton, S.J. et al., “Continuous MLL-ENL expression is necessary to establish a “Hox Code” and maintain immortalization of hematopoietic progenitor cells,” Cancer Res. 65(20):9245-9252 (2005). [cited by applicant]
Hoshimaru, M. et al., “Differentiation of the immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of the V-MYC oncogene,” Proceedings of the National Acadamy of Sciences of USA… [cited by applicant]
Howard, M.J. et al., “Transplantation of apoptosis-resistant embryonic stem cells into the injured rat spinal cord,” Somatosensory & Motor Research 22(1-2):37-44 (2005). [cited by applicant]
Huang et al., “Dynamic Regulation of C-Myc Proto-Oncogene Expression during Lymphocyte Development Revealed by a GFP-c-Myc Knock-In Mouse”, Eur. J. Immunol., vol. 38, No. 2, 2008, pp. 342-349. [cited by applicant]
Huang, et al., “Negative Control of the Myc Protein by the Stress-Responsive Kinase Pak2,” Molecular and Cellular Biology, vol. 24, No. 4, Feb. 2001, pp. 1582-1594. [cited by applicant]
Huettner et al., “Reversibility of Acute B-Cell Leukaemia Induced by BCR-ABL 1,” Nature Genetics, vol. 24, 2000, pp. 57-60. [cited by applicant]
International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/US06/040379, mailed Sep. 24, 2007, 6 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2013/051384, mail date Nov. 13, 2013, 15 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2014/022971 dated Aug. 13, 2014, 12 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2017/064206, mailed Mar. 19, 2018. [cited by applicant]
International Search Report and Written Opinion from PCT/US06/40379 Dtd Sep. 24, 2007. [cited by applicant]
International Search Report and Written Opinion on PCT/US2014/022977, mailed Aug. 28, 2014, 13 pages. [cited by applicant]
International Search Report and Written Opinion on PCT/US2020/027070 dtd Sep. 18, 2020 (13 pages). [cited by applicant]
International Search Report and Written Opinion on PCT/US2020/032702 dtd Nov. 18, 2020. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2008/056896 mailed on Aug. 14, 2008, 5 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2008/082263, mailed on Jun. 25, 2009, 8 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2009/003105, mailed on Jan. 15, 2010, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2009/051242, mailed on Feb. 19, 2010, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2009/055443, mailed on Jun. 30, 2010, 11 pages. [cited by applicant]
International Search Report and Written Opinion, dated Oct. 16, 2018, issued in International Application No. PCT/US2018/044740 (13 pages). [cited by applicant]
International Search Report and Written Opinion, issued in Int'l. App. No. PCT/US2019/062200, 13 pages (Jan. 16, 2020). [cited by applicant]
Iritani et al., “Modulation of T-lymphocyte development, growth and cell size by the Myc antagonist and transcriptional repressor Mad 1”, The EMBO Journal, vol. 21, No. 18, pp. 4820-4830, 2002. [cited by applicant]
Iritani, et al., “c-Myc enhances protein synthesis and cell size during B lymphocyte development”, PNAS, (1999), vol. 96, No. 23, pp. 13180-13185. [cited by applicant]
J. Yu, et al., “Oncology Clinical Bulletin”, Shandong Science and Technology Press, p. 151-152 (2004). [cited by applicant]
Jadlowsky, et al., “Dominant negative mutant Cyclin T1 proteins inhibit HIV transcription by specifically degrading Tat”, Retrovirology, vol. 5, Article 63, 12 pages (2008). [cited by applicant]
Jayapal et al., “Down-regulation of Myc is Essential for Terminal Erythroid Maturation” The Journal of Biological Chemistry, vol. 285, No. 51, pp. 40252-40265, Dec. 17, 2010. [cited by applicant]
Johnson, N.A. et al., “Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival”, Blood, 2009, vol. 114, No. 11, pp. 2273-2279. [cited by applicant]
Ju, et al., “Anti-apoptotic therapy with a Tat fusion protein against excitotoxic insults in vitro and in vivo”, Experimental Neurology 210(2): 602-607 (2008). [cited by applicant]
Kaptein, et al., “Anti-IgM-mediated Regulation of c-myc and Its Possible Relationship to Apoptosis,” JBC, vol. 271, No. 31, Aug. 2, 1996, pp. 18875-18884. [cited by applicant]
Karon, et al., “Temporal sequence of major biochemical events during Blood Bank storage of packed red blood cells”, Blood Transfus 10: 453-461 (2012). [cited by applicant]
Kashio, et al., “A Protein Derived From the Fusion of TAT Peptide and FNK, a Bcl-XL Derivative, Prevents Cochlear Hair Cell Death From Aminoglycoside Ototoxicity In Vivo”, Journal of Neuroscience Research, (2007), vol. … [cited by applicant]
Kelso et al., “Survival of the Myeloid Progenitor Cell Line FDC-P1 is Prolonged by Interferon-y or Interleukin-4”, Growth Factors, vol. 6, No. 3, 1992, pp. 233-242. [cited by applicant]
Kitada, et al., “Reversal of Chemoresistance of Lymphoma Cells by Antisense-Mediated Reduction of bcl-2 Gene Expression”, Antisense Research and Development, (1994), vol. 4, pp. 71-79. [cited by applicant]
Korbling et al., “Allogenic Blood Stem Cell Transplantation: Peripheralization and Yield of Donor-Derived Primitive Hematopoietic Progenitor Cells (CD34+Thy-Idim) and Lymphoid Subsets, and Possible Predictors of Engraft… [cited by applicant]
Krosl et al., “In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein,” Nature Mediciine 9(11):1428-1432 (2003). [cited by applicant]
Lang, et al., “Mechanisms and Significance of Erypotosis, the Suicidal Death of Erythrocytes”, Blood Purification 33(1-3): 125-130 (2012). [cited by applicant]
Laurenti, et al., “Hematopoietic Stem Cell Function and Survival Depend on c-Myc and N-Myc Activity”, Cell Stem Cell 3: 611-624 (2008). [cited by applicant]
Levesque, J-P et al., “The endosteal ‘osteoblastic’ niche and its role in hematopoietic stem cell homing and mobilization”, Leukemia, 2010, vol. 24, pp. 1979-1992. [cited by applicant]
Li et al., “Reconstitution of functional human B lymphocytes in NOD/SCID mice engrafted with ex vivo expanded CD34 cord blood cells”, Experimental Hematology 30(9): 1036-1043 (2002). [cited by applicant]
Littlewood et al., “A modified oestrogen receptor ligand-binding doman as an improved switch for the regulation of heterologous proteins”, Nucleic Acids Research 23(10): 1686-1690 (1995). [cited by applicant]
MacPherson, P. et al., “Activity-dependent gene regulation in conditionally-immortalized muscle precursor cell lines,” J. Cell. Biol. 91(4):821-839 (2004). [cited by applicant]
Maite, et al., “Erythropoietin Can Promote Erythroid Progenitor Survival by Repressing Apoptosis Through Bcl-XL, and Bcl-2”, Blood Journal 88(5): 1576-1582 (1996). [cited by applicant]
McCarthy, “Underground movement”, Nature Reviews Cancer, (2007), vol. 7, 1 page, published online Oct. 11, 2007. [cited by applicant]
McNiece, et al., “Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer”, Hematol. Cell Ther. 41(2): 82-86 (1999). [cited by applicant]
Melkonyan et al., “Electroporation efficiency in mammalian cells is increased by dimethyl sulfoxide (DMSO),” Nucleic Acids Research 24:4356-4357 (1996). [cited by applicant]
Merino et al., “Developmental Regulation of the Bcl-2 Protein and Susceptibility to Cell Death in B Lymphocytes”, The EMBO Journal, vol. 13, No. 3, 1994, pp. 683-691. [cited by applicant]
Miharada et al., “Efficient enucleation of erythroblasts differentiated in vitro from hematopoietic stem and progenitor cells”, Nature Biotechnology, 24(10): 1255-1256, 2006. [cited by applicant]
Miller et al., “Expansion in vitro of adult murine hematopoietic stem cells with transplantable lympho-myeloid reconsituting ability,” PNAS USA 94: 13648-13653 (1997). [cited by applicant]
Momir, et al., “Is erythropoietin a survival factor for red blood cells”, Journal of the American Society of Nephrology, 7(8): 1178-1182 (1996). [cited by applicant]
Moore et al., “In Vitro Maintenance of Highly Purified, Transplantable hematopoietic Stem Cells,” Blood 89(12):4337-4347 (1997). [cited by applicant]
Mooslehner et al., Retroviral Integration Sites in Transgenic Mov Mice Frequently Map in the Vicinity of Transcribed DNA Regions,: J. Virology 64:3056-3058 (1990). [cited by applicant]
Muchmore et al., “X Ray and NMR Structure of Human Bcl-XL, an Inhibitor of Programmed Cell Death”, Nature, vol. 381, May 23, 1996, pp. 335-341. [cited by applicant]
Murphy, et al., “Id2 is dispensable for myc-induced epidermal neoplasia”, Molecular and Cellular Biology 24(5): 2083-2090 (2004). [cited by applicant]
Opferman, et al., “Anti-apoptotic BCL-2 family members in development”, Cell Death and Differentiation 25: 37-45 (2018). [cited by applicant]
Ouyang, et al., “Pathophysiology: the Mechanism of Disease and the Basis of Prevention and Treatment”, Wuhan University Press, 1st Ed., pp. 128-129 (2004). [cited by applicant]
Pan et al., “Reprogramming human fibroblasts using HIV-1 Tat recombinant proteins OCT4, SOX2, KLF4 and c-MYC,” Mol. Biol Rep (2010) 37:2117-2124. [cited by applicant]
Partial Search Report issued on EP Appl. 14778538.0, mailed Jul. 8, 2016. [cited by applicant]
Patel et al., “The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60,” Molecular and Cellular Biology, Dec. 1, 2004, vol. 24, No. 24, pp. 10826-10834. [cited by applicant]
Penuela, et al., “Erythropoietin reduces storage lesions and decreases apoptosis indices in blood bank red blood cells”, Revista Brasileira de Hematologia e Hemoterapia 38(1): 15-20 (2016). [cited by applicant]
Pharmaceutics (Yakuzaigaku), 64(3), 2004, p. 164-167 (English translation not available). [cited by applicant]
Pierelli et al., “Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF-B 1 is a cell cycle-independent effect and influences their hematopoietic potential,”Blood 95:300… [cited by applicant]
Pinto et al., “Hematopoietic progenitor/stem cells immortalized by Lhx2 generate functional hematopoietic cells in vivo,” Blood 99(11):3939-3946 (2002). [cited by applicant]
Podsypanina, K. et al., “Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by MYC and mutant Kras,” PNAS 105(13):5242-5247 (2008). [cited by applicant]
Polenakovic et al., “Is Erythropoietin a Survival Factor for Red Blood Cells,” J. Am. Soc. Nephrol, vol. 7, 1996, pp. 1178-1182. [cited by applicant]
Pollock, K. et al., “A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke,” Exp. Neurol., (2006), vol. 199, No. 1, pp. 143-155. [cited by applicant]
Prochownik et al., “Deregulated expression of c-myc by murine erythroleukaemia cells prevents differentiation,” Nature, vol. 322, Aug. 28, 1986, pp. 848-850. [cited by applicant]
Qin et al., “Nuclear Factor KB Nuclear Translocation Upregulates c-Myc and p53 Expression during NMDA Receptor-Mediated Apoptosis in Rat Striatum”, The Journal of Neuroscience, vol. 19, No. 10, May 15, 1999, pp. 4023-40… [cited by applicant]
Rabbitts, et al., “Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle”, EMBO Journal, (1985), vol. 4, No. 8, pp. 2009-2015. [cited by applicant]
Radhakrishnan et al., “A Novel Transcriptional Inhibitor Induces Apoptosis in Tumor Cells and Exhibits Antiangiogenic Activity”, Cancer Research, vol. 66, No. 6, Mar. 15, 2006, pp. 3264-3270. [cited by applicant]
Raymon, H.K. et al., “Immortalized human dorsal root ganglion cells differentiate into neurons with nociceptive properties,” J. Neuroscience 19(13):5420-5428 (1999). [cited by applicant]
Refaeli, et al., “The protooncogene MYC can break B cell tolerance”, Proceedings of the National Academy of Sciences of the U.S.A. 102(11): 4097-4102 (2005). [cited by applicant]
Refaeli, Y, “The B-Cell Antigen Receptor and Overexpression of MYC Can Cooperate in the Genesis of B-Cell Lymphomas”, PLOS Biology, vol. 6, No. 6, e152, 2008, pp. 1208-1225. [cited by applicant]
Richter, et al., “Lhx.2 expression in hematopoietic progenitor/stem cells in vivo causes a chronic myeloproliferative disorder and altered globin expression,” J. Hematol., (2003), 88(12):1336-1347. [cited by applicant]
Roh et al., “Transgenic Mice for Cre-Inducible Overexpression of the Oncogenes c-MYC and Pim-1 in Multiple Tissues”, Genesis: The Journal of Genetics and Development, vol. 44 pp. 447-453, (2006). [cited by applicant]
Rosenwald, et al., “Increased Expression of Eukaryotic Translation Inhibition Factors eIF-4E and eIF-2alpha in Response to Growth Induction by C-MYC”, Proc. Natl. Acad. Sci. USA, vol. 90, pp. 6175-6178, (1993). [cited by applicant]
Rubinstein, et al., “Ex Vivo Interleukin-12-Priming During CD8 T Cell Activation Dramatically Improves Adoptive T Cell Transfer Antitumor Efficacy in a Lymphodepleted Host”, J. Am. Coll. Surg. 214(4): 700-707 (2002). [cited by applicant]
Rudolph et al., “Expression of Mad1 in T cells leads to reduced thymic cellularity and impaired mitogen-induced proliferation”, Oncogene, 2001, vol. 20, pp. 1164-1175. [cited by applicant]
Satoh, et al, “Roles for c-Myc in Self-renewal of Hematopoietic Stem Cells,” The Journal of Biological Chemistry 279(24): 24986-24993 (2004). [cited by applicant]
Sauer, “Inducible Gene Targeting in Mice Using the Cre/Iox System,” Methods, (1998), vol. 14, No. 4, pp. 381-392. [cited by applicant]
Schiedlmeier et al., “High-level Ectopic HOXB4 Expression Confers a Profound in Vivo Competitive Growth Advantage on Human Cord Blood CD34 Cells, but Impairs Lymphomyeloid Differentiation”, Blood, vol. 101, No. 5, Mar. … [cited by applicant]
Schmidt et al., “Transgenic Mice Bearing the Human c-myc Gene Activated by an Immunoglobulin Enhancer: A pre-B-cell Lymphoma Model”, National Academy of Sciences, vol. 85, pp. 6047-6051 (1988). [cited by applicant]
Schneider, et al., “Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90”, PNAS 93: 14536-14541 (Dec. 1996). [cited by applicant]
Schroy, et al., “A Simple Method for Freezing and Thawing Cultured Cells,” Methods in Cell Science (formerly known as TCA Manual), (1976), vol. 2, No. 1, pp. 309-310. [cited by applicant]
Schwarze et al., “Protein transduction: unrestricted delivery into all cells?” Trends Cell Biol. 10:290-295 (2000). [cited by applicant]